Vidac Pharma secures approval for next phase of clinical study of lead asset in Cutaneous T-Cell Lymphoma
London (UK), March 12, 2024 (07:30 CET) – Vidac Pharma Holdings Plc. (Hamburg and Stuttgart: T9G; ISIN:GB00BM9XQ619; WKN: A3DTUQ), a clinical-stage…